OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EAPI58

Euroapi SA

PharmaceuticalsVerified

Euroapi's capital structure is characterized by a lack of detailed liquidity metrics, as liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot does not provide extended ratios such as ROIC or margins, limiting the ability to assess capital efficiency or profitability in detail. Profitability and returns are not quantifiable at this time due to the absence of key financial metrics in the valuation snapshot. The company's performance against industry_config preferred metrics and cohort medians cannot be determined without access to normalized financial data. This lack of data also prevents a direct comparison of Euroapi's margins or return on invested capital to industry benchmarks. Euroapi's revenue is derived from the sale of APIs and excipients, but the input data does not provide a breakdown of revenue by geographic region or business segment. Without this information, it is not possible to assess the company's exposure to geographic concentration or segment-specific performance. The company's growth trajectory is not quantifiable due to the absence of outlook data and revenue history in the input. Analysts have provided a mean price target of 1.40 EUR and a median price target of 1.50 EUR, but these do not reflect a clear direction for revenue or earnings growth. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, and no adjustments have been applied to the valuation metrics. However, the lack of detailed financial data limits the ability to fully evaluate the company's risk profile. Recent events and filings are not detailed in the input data, so no specific events or transcripts can be cited to inform the company's current strategic or operational direction. Analysts have issued two "Hold" recommendations, with no "Buy" or "Strong Buy" ratings, indicating a neutral outlook from the investment community.

30-day price · EAPI+0.20 (+15.8%)
Low$1.22High$1.54Close$1.45As of13 May, 00:00 UTC
Profile
CompanyEuroapi SA
TickerEAPI.PA
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Euroapi SA is a pharmaceutical company that provides active pharmaceutical ingredients (APIs) and excipients to the global pharmaceutical industry, primarily generating revenue through the production and sale of these ingredients to drug manufacturers.

Classification. Euroapi is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a confidence level of 0.92 based on verified market data.

Euroapi's capital structure is characterized by a lack of detailed liquidity metrics, as liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot does not provide extended ratios such as ROIC or margins, limiting the ability to assess capital efficiency or profitability in detail. Profitability and returns are not quantifiable at this time due to the absence of key financial metrics in the valuation snapshot. The company's performance against industry_config preferred metrics and cohort medians cannot be determined without access to normalized financial data. This lack of data also prevents a direct comparison of Euroapi's margins or return on invested capital to industry benchmarks. Euroapi's revenue is derived from the sale of APIs and excipients, but the input data does not provide a breakdown of revenue by geographic region or business segment. Without this information, it is not possible to assess the company's exposure to geographic concentration or segment-specific performance. The company's growth trajectory is not quantifiable due to the absence of outlook data and revenue history in the input. Analysts have provided a mean price target of 1.40 EUR and a median price target of 1.50 EUR, but these do not reflect a clear direction for revenue or earnings growth. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, and no adjustments have been applied to the valuation metrics. However, the lack of detailed financial data limits the ability to fully evaluate the company's risk profile. Recent events and filings are not detailed in the input data, so no specific events or transcripts can be cited to inform the company's current strategic or operational direction. Analysts have issued two "Hold" recommendations, with no "Buy" or "Strong Buy" ratings, indicating a neutral outlook from the investment community.
Key takeaways
  • Euroapi's liquidity risk cannot be assessed due to missing balance-sheet data.
  • Profitability and return metrics are not available, limiting the ability to compare with industry benchmarks.
  • Revenue concentration by segment or geography is not disclosed in the input data.
  • Analysts have issued a neutral outlook, with no strong buy or buy ratings.
  • The company's growth trajectory is unclear due to the absence of revenue history and outlook data.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$892.8M-$12.8M-$8.1M-$20.7M
FY-3$980.9M-$800.0k-$15.1M-$108.0M
FY-2$1.02B-$234.3M-$189.8M-$243.5M
FY-1$919.2M-$120.4M-$130.6M-$179.3M
FY0$852.6M-$130.6M-$211.1M-$219.8M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.62B$1.01B$10.3M
FY-3$1.74B$1.11B$74.5M
FY-2$1.61B$927.7M$34.5M
FY-1$1.49B$983.5M$73.0M
FY0$1.30B$788.0M$113.8M
PeriodOCFCapExFCFSBC
FY-4$71.7M-$88.6M-$20.7M
FY-3$44.8M-$167.4M-$108.0M
FY-2$5.1M-$132.8M-$243.5M
FY-1$122.9M-$108.0M-$179.3M
FY0$128.6M-$78.5M-$219.8M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricEAPIActivity
Op margin7.7% medp25 -2.4% · p75 15.5%
Net margin5.9% medp25 -3.8% · p75 12.8%
Gross margin45.5% medp25 31.1% · p75 62.9%
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-7.0% medp25 -14.9% · p75 -3.2%
Debt / equity25.0% medp25 3.8% · p75 63.3%
Observations
IR observations
Mean price target1.40 EUR
Median price target1.50 EUR
High price target1.70 EUR
Low price target1.00 EUR
Mean recommendation3.60 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count2.00
Sell count3.00
Strong-sell count0.00
Mean EPS estimate-0.09 EUR
Last actual EPS-1.63 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 02:11 UTC#4bc494d1
Market quoteclose EUR 1.50 · shares 0.10B diluted
no public URL
2026-05-12 02:11 UTC#ade52883
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 19:46 UTCJob: 23695574